<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Congenital third-degree (complete) atrioventricular block
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Congenital third-degree (complete) atrioventricular block
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Congenital third-degree (complete) atrioventricular block
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Authors:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            William H Sauer, MD
           </a>
          </dd>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Edward P Walsh, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Mark S Link, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Susan B Yeon, MD, JD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            May 16, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Atrioventricular (AV) block is defined as a delay or interruption in the transmission of an impulse from the atria to the ventricles due to an anatomical or functional impairment in the conduction system. The conduction disturbance can be transient or permanent, with conduction that is delayed, intermittent, or absent. Commonly used terminology includes:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         First-degree AV block – Delayed conduction from the atrium to the ventricle (defined as a prolonged PR interval of &gt;200 milliseconds) without interruption in atrial to ventricular conduction.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second-degree AV block – Intermittent atrial conduction to the ventricle, often in a regular pattern (eg, 2:1, 3:2), or higher degrees of block, which are further classified into Mobitz type I (Wenckebach) and Mobitz type II second-degree AV block.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Third-degree (complete) AV block – No atrial impulses conduct to the ventricle.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         High-grade AV block – Two or more consecutive blocked P waves.
        </p>
        <p>
        </p>
        <p>
         Atrioventricular block is considered to be "congenital" when it occurs spontaneously in a fetus or young child. Congenital complete heart block (CHB) was first described in 1901 by Morquio, who also noted the familial occurrence and the association with Stokes-Adams attacks and death [
         <a href="#rid1">
          1
         </a>
         ]. The presence of fetal bradycardia (40 to 80 beats per minute) as a manifestation of CHB was first noted in 1921 and is the initial sign of this disorder in many cases [
         <a href="#rid2">
          2
         </a>
         ].
        </p>
        <p>
         The epidemiology, etiologies, clinical presentation, diagnosis, treatment, and prognosis associated with congenital CHB will be presented here. Discussions of noncongenital complete AV block are presented separately. (See
         <a class="medical medical_review" href="/z/d/html/907.html" rel="external">
          "Etiology of atrioventricular block"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/911.html" rel="external">
          "Third-degree (complete) atrioventricular block"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2482259254">
         <span class="h1">
          EPIDEMIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The incidence of congenital CHB in the general population varies between 1 in 15,000 to 1 in 22,000 live-born infants [
         <a href="#rid3">
          3,4
         </a>
         ]. Injury to fetal conduction tissues caused by transplacental exposure to maternal autoantibodies related to systemic lupus erythematosus or Sjögren's disease is responsible for 60 to 90 percent of cases of congenital CHB overall [
         <a href="#rid5">
          5-7
         </a>
         ]. Among women with anti-Ro/SSA and/or anti-La/SSB antibodies, fetal/neonatal CHB occurs in approximately 2 percent of pregnancies [
         <a href="#rid8">
          8,9
         </a>
         ]. However, once a woman has given birth to an infant with autoimmune CHB block, the recurrence rate in subsequent pregnancies rises to approximately 15 percent. (See
         <a class="medical medical_review" href="/z/d/html/1818.html" rel="external">
          "The anti-Ro/SSA and anti-La/SSB antigen-antibody systems"
         </a>
         .)
        </p>
        <p>
         As many as 40 percent of cases of congenital CHB do not present until later in childhood (mean age five to six years) [
         <a href="#rid7">
          7
         </a>
         ]. Only rarely do these patients (5 percent) have proven autoimmune etiology [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          ETIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         The etiologies of congenital CHB include the following [
         <a href="#rid10">
          10
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Autoimmune antibodies.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Structural heart abnormalities due to congenital heart disease (eg, congenitally corrected transposition of the great arteries, endocardial cushion defects).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Idiopathic familial congenital CHB.
        </p>
        <p>
        </p>
        <p>
         Complete heart block may also be seen in the fetus or young child as a consequence of myocarditis or mechanical trauma from surgical or transcatheter interventions; however, these acquired forms are not considered "congenital."
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Autoimmune congenital CHB
         </span>
         <span class="headingEndMark">
          —
         </span>
         Autoimmune heart block typically begins in utero, though clinical detection may occasionally be delayed until after birth or during early childhood [
         <a href="#rid11">
          11
         </a>
         ]. In most cases, the block is third degree, with lower-grade block seen only occasionally. The mechanism is understood to involve damage to developing specialized conduction tissue from passive transplacental passage of maternal autoantibodies to Ro/SSA and/or La/SSB intracellular ribonuclear proteins [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
         The risk of CHB in an individual fetus does not correlate directly with the maternal autoantibody titer. Importantly, the majority of mothers who give birth to a child with autoimmune CHB have never had symptoms of connective tissue disease up to time of delivery despite their positive serology. Some affected newborns may present with a multisystem neonatal lupus syndrome that can include skin rash, hepatobiliary disease, and thrombocytopenia [
         <a href="#rid12">
          12
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H2056037574">
         <span class="h2">
          Congenital CHB related to congenital heart defects
         </span>
         <span class="headingEndMark">
          —
         </span>
         Certain forms of congenital heart disease are associated with developmental abnormalities of the AV conduction tissues [
         <a href="#rid13">
          13
         </a>
         ].
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          L-looped transposition of the great arteries (L-TGA)
         </strong>
         – In L-TGA (also called "congenitally corrected" transposition of the great arteries)  (
         <a class="graphic graphic_figure graphicRef83845" href="/z/d/graphic/83845.html" rel="external">
          figure 1
         </a>
         ), the compact AV node develops outside of Koch's triangle in an unusual anterior location near the base of the right atrial appendage. This displaced node is often feeble and can deteriorate over time so that complete heart block is seen in as many as 5 percent of these patients at birth, and in more than 25 percent by adulthood. (See
         <a class="medical medical_review" href="/z/d/html/83229.html" rel="external">
          "L-transposition of the great arteries (L-TGA): Anatomy, clinical features, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Endocardial cushion defects
         </strong>
         – Displacement of the AV node also occurs in patients with endocardial cushion defects (ie, primum atrial septal defects or complete AV canal defects)  (
         <a class="graphic graphic_figure graphicRef86346" href="/z/d/graphic/86346.html" rel="external">
          figure 2
         </a>
         ). These hearts do not have a proper triangle of Koch, and the compact node is consequently displaced in a posterior direction beneath the mouth of coronary sinus. Similar to L-TGA, AV nodal function can be suboptimal in endocardial cushion defects, with complete heart block at birth in some individuals, and a significant risk of surgically-induced block following repairs. (See
         <a class="medical medical_review" href="/z/d/html/85595.html" rel="external">
          "Clinical manifestations and diagnosis of atrioventricular (AV) canal defects"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Syndromes with simple atrial septal defects
         </strong>
         – Congenitally impaired AV nodal function can also be observed in some simple cases of atrial septal defect among patients with Holt-Oram syndrome, an autosomal dominant disorder causing cardiac and upper-limb abnormalities that involves a mutation on the
         <em>
          TBX5
         </em>
         gene [
         <a href="#rid14">
          14
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/5754.html" rel="external">
          "Isolated atrial septal defects (ASDs) in children: Classification, clinical features, and diagnosis", section on 'Genetic disorders'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H2486736822">
         <span class="h2">
          Idiopathic familial congenital CHB
         </span>
         <span class="headingEndMark">
          —
         </span>
         Non-immune CHB in patients with a structurally normal heart has also been described as an idiopathic disorder with a strong familial tendency. In a retrospective cohort of 141 children with AV block diagnosed in utero or up to age 15 years (51 percent female, 84 percent asymptomatic, 71 percent with complete AV block on presentation, with an additional 21 percent progressing from incomplete to complete AV block), 112 patients (79 percent) received permanent pacemakers, most prophylactically in asymptomatic patients (70 of 112 patients [63 percent]) [
         <a href="#rid15">
          15
         </a>
         ]. Familial screening electrocardiograms (ECGs) were obtained from 130 parents of patients in the cohort and were compared with 130 matched healthy controls [
         <a href="#rid16">
          16
         </a>
         ]. Parents of the children with AV block were significantly more likely to have conduction abnormalities compared with healthy controls, including complete or incomplete right bundle branch block (39 versus 2 percent), complete or incomplete left bundle branch block (15 versus 3 percent), and PR prolongation (19 versus 0 percent).
        </p>
        <p>
         Progressive AV block has also been reported in association with an extracardiac phenotype that includes a brachyfacial abnormality, finger deformity, and dental dysplasia [
         <a href="#rid17">
          17
         </a>
         ]. Members of these two unrelated families shared a common mutation in the third exon of the gene encoding for connexin-45, a gap junction channel involved in electrical signal propagation in the sinoatrial (SA) node, AV node, and His-Purkinje system.
        </p>
        <p class="headingAnchor" id="H6036308">
         <span class="h1">
          PATHOPHYSIOLOGY
         </span>
         <span class="headingEndMark">
          —
         </span>
         Most cases of congenital CHB are immune-mediated and are characterized pathologically by fibrous tissue that either replaces the atrioventricular (AV) node and its surrounding tissue or by an interruption between the atrial myocardium and the AV node [
         <a href="#rid18">
          18-26
         </a>
         ]. The net effect is that the block is usually at the level of the AV node [
         <a href="#rid20">
          20,22,24,27,28
         </a>
         ], allowing junctional escape rhythms that can usually support the fetal and neonatal circulation, at least temporarily [
         <a href="#rid12">
          12,29
         </a>
         ]. The primary injury is caused by the binding of anti-Ro/SSA and/or anti-La/SSB antibodies to the developing AV node and its surrounding tissue [
         <a href="#rid9">
          9,18,30
         </a>
         ]. Both Ro/SSA and La/SSB antigens are abundant in fetal heart tissue between 18 and 24 weeks [
         <a href="#rid30">
          30
         </a>
         ]. Apoptosis induces translocation of Ro/SSA and La/SSB to the surface of fetal cardiomyocytes; anti-Ro and anti-La antibodies then bind to the surface of the fetal cardiocytes and induce the release of tumor necrosis factor by macrophages, which then results in fibrosis [
         <a href="#rid31">
          31
         </a>
         ].
        </p>
        <p>
         In addition to inducing tissue damage, anti-Ro/SSA and/or anti-La/SSB antibodies inhibit calcium channel activation or the cardiac L- and T- type calcium channels themselves; L-type channels are crucial to action potential propagation and conduction in the AV node [
         <a href="#rid32">
          32,33
         </a>
         ].
        </p>
        <p>
         Congenital CHB in patients with congenital heart defects is directly related to abnormalities in the embryologic development of the specialized atrioventricular conduction tissues that lead to displacement and functional impairment of the AV node and/or His bundle.
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         The manifestations of congenital CHB vary according to the age at presentation, underlying etiology, ventricular rate of the escape rhythm, and ventricular function. Patients with autoimmune congenital CHB tend to present earlier than those with CHB due to other causes [
         <a href="#rid34">
          34
         </a>
         ]. In addition to atrioventricular conduction defects, in a small number of cases autoimmune CHB can be associated with sinoatrial node dysfunction as well as a more diffuse cardiomyopathy that can result in depressed ventricular function and endocardial fibroelastosis [
         <a href="#rid7">
          7,9,18,35,36
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis", section on 'Other cardiac abnormalities'
         </a>
         .)
        </p>
        <p>
         Autoimmune heart block typically begins in utero, though clinical detection may occasionally be delayed until after birth or during early childhood. In most cases, the block is third degree, with lower-grade block seen only occasionally. The noncardiac manifestations of neonatal lupus resolve as maternal antibodies dissipate in the infant, but cardiac damage tends to be irreversible.
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h2">
          In utero presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         Congenital heart block may present with fetal bradycardia between 18 and 28 weeks of gestation [
         <a href="#rid7">
          7,11,12
         </a>
         ]. The clinical manifestations, diagnosis, and approach to management of intrauterine congenital CHB are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias", section on 'Heart block'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Neonatal presentation
         </span>
         <span class="headingEndMark">
          —
         </span>
         The primary finding in neonates with congenital CHB is a slow heart rate that is usually less than 100 beats per minute. Neonates with congenital CHB otherwise have few specific physical examination findings, although they may appear pale or diaphoretic related to the reduction in cardiac output. Other clinical clues in the neonate may include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent cannon waves in the neck
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Variable intensity of the first heart sound (see
         <a class="medical medical_review" href="/z/d/html/1079.html" rel="external">
          "Auscultation of heart sounds"
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Intermittent gallops and murmurs
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Signs of congestive heart failure (eg, crackles on lung examination, elevated jugular venous pulsations, peripheral edema, etc)
        </p>
        <p>
        </p>
        <p>
         As with cases presenting in utero, almost all presenting in the neonatal period (90 percent in one series) are due to maternal autoantibodies [
         <a href="#rid7">
          7,37
         </a>
         ]. First- or second-degree AV block found in infants at birth can progress to CHB and should be followed carefully [
         <a href="#rid35">
          35,38
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Presentation in later childhood
         </span>
         <span class="headingEndMark">
          —
         </span>
         Up to 40 percent of patients with congenital CHB present later in childhood. Reasons for the late presentation are speculative, but likely relate to an intermittent early course or a higher ventricular rate of the escape rhythm [
         <a href="#rid39">
          39
         </a>
         ]. The primary finding in children with congenital CHB is a slow heart rate with or without bradycardia-related symptoms, including reduced exercise tolerance and presyncope or syncope (Stokes-Adams attacks) [
         <a href="#rid7">
          7,40
         </a>
         ]. Sudden death has also rarely been described [
         <a href="#rid29">
          29,41,42
         </a>
         ].
        </p>
        <p>
         Although congenital CHB may be intermittent when first detected, it usually becomes persistent over time [
         <a href="#rid7">
          7
         </a>
         ]. While congenital CHB diagnosed for the first time later in childhood may be congenital in origin, escaping notice because of a higher ventricular rate and the absence of symptoms, patients who present later in childhood likely have preserved AV conduction at birth and acquire progressive AV nodal disease thereafter [
         <a href="#rid7">
          7
         </a>
         ]. In a single-center study of 102 patients with congenital CHB diagnosed over a 34-year period, the number of presentations later in childhood remained constant from 1980 to 1998 despite the introduction of fetal echocardiography and the wide availability of heart rate monitoring during pregnancy and labor, suggesting that AV conduction is preserved at birth and becomes abnormal at a later time in a subset of patients [
         <a href="#rid7">
          7
         </a>
         ].
        </p>
        <p>
         Maternal autoantibody exposure accounts for almost all cases presenting in utero or the neonatal period, but for only a few cases occurring at older ages (5 percent in one report) [
         <a href="#rid7">
          7
         </a>
         ]. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/6402.html" rel="external">
          "Neonatal lupus: Epidemiology, pathogenesis, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3460898515">
         <span class="h1">
          DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         In nearly all cases, the diagnosis of complete heart block can be made by obtaining a surface ECG, ideally a full 12-lead ECG, though a single-lead rhythm strip is sometimes adequate if a full 12-lead ECG cannot be obtained. The diagnosis is usually suspected when a slow pulse is detected and heart block is confirmed by ECG or by ambulatory ECG monitoring [
         <a href="#rid7">
          7,40,41
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3967755709">
         <span class="h1">
          DIFFERENTIAL DIAGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Complete heart block has a relatively unique appearance on the ECG, with evidence of atrial (P waves) and ventricular (QRS complexes) activity that are independent of each other, and an atrial rate faster than the ventricular rate. Rarely, complete AV block can occur in which the atrial rate is exactly twice the ventricular rate (eg, atrial rate of 80 beats per minute with a ventricular rate of 40 beats per minute), in which case the appearance on ECG could be similar to that of second-degree AV (ie, 2:1) block. However, any slight variation in the exact multiples should result in variations on the ECG that allow the distinction between third-degree (complete) AV block and second-degree AV block.
        </p>
        <p>
         In utero CHB must be differentiated from benign bradycardia caused by frequent blocked premature atrial complexes (also referred to a premature atrial beat, premature supraventricular complex, or premature supraventricular beat), which can be reliably distinguished on the basis of the fetal echocardiogram.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h1">
          TREATMENT
         </span>
        </p>
        <p class="headingAnchor" id="H1312367830">
         <span class="h2">
          In utero treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The management options for congenital CHB in utero are limited, and treatment of the fetus with CHB is primarily expectant. Fortunately, the fetus will tolerate the slow escape rhythm in the majority of cases. If hydrops fetalis or other signs of fetal distress should develop, early delivery and emergency pacing may be needed. The approach to in utero treatment of fetal CHB is discussed in detail separately. (See
         <a class="medical medical_review" href="/z/d/html/113264.html" rel="external">
          "Neonatal lupus: Management and outcomes", section on 'In utero management'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6765.html" rel="external">
          "Fetal arrhythmias", section on 'Heart block'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H3863143467">
         <span class="h2">
          Postnatal treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         For neonates and children who present later with congenital CHB, the principal therapeutic decision involves the need for, and the potential timing of, permanent pacemaker insertion. For older children who are able to express themselves about symptoms, the presence or absence of symptoms will help guide the decision. Patients with an adequate ventricular heart rate and no symptoms can usually be followed with serial observation, while symptomatic patients (typically those with a slower ventricular heart rate) will require a permanent pacemaker [
         <a href="#rid43">
          43
         </a>
         ]. Most patients (approximately 90 percent or greater) ultimately have a pacemaker inserted  (
         <a class="graphic graphic_figure graphicRef55309" href="/z/d/graphic/55309.html" rel="external">
          figure 3
         </a>
         ), regardless of when CHB developed (ie, in utero or following delivery) [
         <a href="#rid7">
          7,41
         </a>
         ].
        </p>
        <p>
         Our approach to pacemaker implantation is in general agreement with the professional society guidelines for management of bradycardia, which specifically address the population of patients with congenital CHB [
         <a href="#rid43">
          43-45
         </a>
         ]. Pacemaker implantation was recommended (class I) or felt to be reasonable (class IIa) for patients with congenital CHB and the following characteristics:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptomatic bradycardia or low cardiac output (class I).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Wide QRS escape rhythm, complex ventricular ectopy, or ventricular dysfunction (class I).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Asymptomatic adults with congenital CHB (class IIa).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants with normal anatomy and a ventricular rate less than 55 beats per minute (class I).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Infants with other structural congenital heart disease and a ventricular rate less than 70 beats per minute (class I).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Children beyond the first year of life with an average heart rate less than 50 beats per minute, or abrupt pauses two to three times the basic R-R cycle length (class IIa).
        </p>
        <p>
        </p>
        <p>
         The type of pacemaker implanted is based primarily upon patient age/size, as well as the presence or absence of congenital heart defects. Implants for infants and very young children will usually require epicardial leads due to small caliber of the standard insertion veins used for transvenous devices, as well as the expectation for thoracic growth that may eventually place tension on transvenous leads [
         <a href="#rid46">
          46
         </a>
         ]. Epicardial leads are also used in patients of any age with septal defects that allow intracardiac shunting and thus increase the risk of thromboembolic complications [
         <a href="#rid47">
          47
         </a>
         ]. A transvenous dual-chamber pacemaker is preferred at most centers when there are no significant size constraints or other contraindications. When feasible, consideration should be given to techniques for ventricular lead placement that activate the native His bundle or left bundle branch [
         <a href="#rid48">
          48
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/950.html" rel="external">
          "Modes of cardiac pacing: Nomenclature and selection"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h1">
          PROGNOSIS
         </span>
         <span class="headingEndMark">
          —
         </span>
         CHB presenting in utero or the neonatal period, which is mostly due to maternal autoantibodies, is associated with a high early mortality [
         <a href="#rid10">
          10,49-51
         </a>
         ]. The outcome for patients diagnosed as neonates is better than for those diagnosed in utero. Infants and young children with complete heart block who are asymptomatic usually remain so until later childhood, adolescence, or adulthood [
         <a href="#rid3">
          3,52
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/113264.html" rel="external">
          "Neonatal lupus: Management and outcomes"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Among 175 cases of congenital CHB diagnosed in the fetus, 29 (17 percent) died either in utero or within the first three months of life [
         <a href="#rid7">
          7,12
         </a>
         ]. Survival appears to relate to gestational age at birth, with offspring born before 34 weeks having a higher mortality rate than those born later (52 versus 9 percent) [
         <a href="#rid12">
          12
         </a>
         ]. Infants with first- or second-degree heart block at birth can progress to complete heart block [
         <a href="#rid12">
          12,35,38
         </a>
         ]. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In a single-center cohort of 33 patients who presented in the neonatal period, five had signs of heart failure, but none had hydrops fetalis [
         <a href="#rid7">
          7
         </a>
         ]. None died within the first six months, but two died at 0.9 and 1.5 years of age.
        </p>
        <p>
        </p>
        <p>
         Prognosis is generally excellent among infants and those diagnosed later in childhood [
         <a href="#rid10">
          10
         </a>
         ]. However, exercise limitation and even mortality in childhood are not negligible [
         <a href="#rid40">
          40,53,54
         </a>
         ]. Children with a mean heart rate below 50 beats per minute and evidence of an unstable junctional escape rhythm may be at particular risk [
         <a href="#rid37">
          37,40
         </a>
         ]. Even patients who have been asymptomatic throughout childhood are at increased risk of sudden death. In a review of 102 patients who were without symptoms through age 15, 27 (26 percent) had a subsequent syncopal episode, eight of which were fatal [
         <a href="#rid41">
          41
         </a>
         ].
        </p>
        <p>
         Those patients who do not experience symptoms or syncopal attacks may still suffer physiologic consequences of bradycardia. The ventricular rate tends to fall slowly with age [
         <a href="#rid41">
          41
         </a>
         ]. To compensate for the slow heart rate, the heart enlarges to produce a higher stroke volume; in some cases, this can lead to voltage criteria for left ventricular enlargement and nonspecific ST-T wave changes [
         <a href="#rid55">
          55
         </a>
         ] as well as to heart failure [
         <a href="#rid56">
          56,57
         </a>
         ].
        </p>
        <p>
         In general, the prognosis following pacemaker implantation is excellent [
         <a href="#rid37">
          37,58,59
         </a>
         ]. However, a significant number of patients (5 to 11 percent) develop heart failure over the long-term, even if a pacemaker is inserted [
         <a href="#rid56">
          56,57,60
         </a>
         ]. In a study of 149 patients followed for 10 years, 6 percent developed a dilated cardiomyopathy by 6.5 years of age; risk factors included anti-Ro/SSA or anti-La/SSB antibodies, increased heart size at initial evaluation, and the absence of improvement with a pacemaker [
         <a href="#rid57">
          57
         </a>
         ]. Patients diagnosed prior to one month of age are more likely to have left ventricular systolic dysfunction both prior to permanent pacemaker implantation and over the long-term [
         <a href="#rid37">
          37
         </a>
         ]. In another study of 114 subjects followed over a period of 40 years, 26 subjects (23 percent) reached the primary composite outcome of death, LV systolic dysfunction, heart failure, cardiomyopathy, or use of cardiac resynchronization therapy, with an incidence rate of 2.2 per 100 person-years [
         <a href="#rid60">
          60
         </a>
         ]. The primary outcome occurred at a median of 3.1 years after diagnosis.
        </p>
        <p>
         While the development of heart failure in such patients may be a consequence of myocardial fibrosis associated with CHB [
         <a href="#rid56">
          56
         </a>
         ], heart failure is also a well-recognized long-term consequence of right ventricular pacing with consequent ventricular asynchrony [
         <a href="#rid61">
          61
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/950.html" rel="external">
          "Modes of cardiac pacing: Nomenclature and selection", section on 'Modes to minimize ventricular pacing'
         </a>
         ).
        </p>
        <p>
         Patients with congenital heart block who develop ventricular dysfunction in the setting of chronic right ventricular pacing will usually benefit from upgrading to cardiac resynchronization with addition of a left ventricular pacing lead [
         <a href="#rid62">
          62
         </a>
         ]. An alternative for this patient group is His bundle pacing as a method to mitigate detrimental effects of asynchronous right ventricular pacing [
         <a href="#rid63">
          63
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/3475.html" rel="external">
          "Cardiac resynchronization therapy in heart failure: Indications and choice of system"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H18366368">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/112356.html" rel="external">
          "Society guideline links: Cardiac implantable electronic devices"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H189979181">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17118.html" rel="external">
          "Patient education: Heart block in adults (The Basics)"
         </a>
         and
         <a class="medical medical_basics" href="/z/d/html/83745.html" rel="external">
          "Patient education: Heart block in children (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H6036270">
         <span class="h1">
          SUMMARY AND RECOMMENDATIONS
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Congenital third-degree (complete) heart block (CHB), a relatively rare disorder affecting between 1 in 15,000 to 1 in 22,000 live-born infants, may result from autoimmune antibodies, structural heart abnormalities due to congenital heart disease, or may be idiopathic. Autoimmune CHB due to maternal auto antibodies that cross the placenta is responsible for 60 to 90 percent of cases of congenital CHB overall. (See
         <a class="local">
          'Epidemiology'
         </a>
         above and
         <a class="local">
          'Etiology'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The manifestations of congenital CHB vary according to the age at presentation, underlying etiology, ventricular rate of the escape rhythm, and ventricular function. The primary finding in neonates with congenital CHB is a slow heart rate that is usually less than 100 beats per minute. Neonates with congenital CHB otherwise have few specific physical examination findings, although they may appear pale or diaphoretic related to the reduction in cardiac output. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In nearly all cases, the diagnosis of complete heart block can be made by obtaining a surface ECG. The diagnosis is usually suspected when a slow pulse is detected and heart block is confirmed by ECG or by ambulatory ECG monitoring. (See
         <a class="local">
          'Diagnosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For neonates and children who present later with congenital CHB, the principal therapeutic decision involves the need for and the potential timing of permanent pacemaker insertion. For older children who are able to express themselves about symptoms, the presence or absence of symptoms will help guide the decision. Patients with an adequate ventricular heart rate and no symptoms can usually be followed with serial observation, while symptomatic patients (typically those with a slower ventricular heart rate) will require a permanent pacemaker. In general, the prognosis following pacemaker implantation is excellent. (See
         <a class="local">
          'Treatment'
         </a>
         above and
         <a class="local">
          'Prognosis'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H235901103">
         <span class="h1">
          ACKNOWLEDGMENT
         </span>
         <span class="headingEndMark">
          —
         </span>
         The UpToDate editorial staff acknowledges Leonard Ganz, MD, FHRS, FACC, who contributed to an earlier version of this topic review.
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Morquio, L . Sur une maladie infantile et familiale characterisée par des modifications permanentes du pouls, des attaques syncopales et epileptiforme et la mort subite. Arch Méd d'Enfants 1901; 4:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           White, P, Eustis, R . Congenital heart block. Am J Dis Child 1921; 22:299.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaëlsson M, Engle MA. Congenital complete heart block: an international study of the natural history. Cardiovasc Clin 1972; 4:85.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11:301.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Johansen AS, Herlin T. [Neonatal lupus syndrome. Association with complete congenital atrioventricular block]. Ugeskr Laeger 1998; 160:2521.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ross BA. Congenital complete atrioventricular block. Pediatr Clin North Am 1990; 37:69.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jaeggi ET, Hamilton RM, Silverman ED, et al. Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years. J Am Coll Cardiol 2002; 39:130.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brucato A, Frassi M, Franceschini F, et al. Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women. Arthritis Rheum 2001; 44:1832.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon JP, Kim MY, Copel JA, Friedman DM. Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient. Arthritis Rheum 2001; 44:1723.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brito-Zerón P, Izmirly PM, Ramos-Casals M, et al. Autoimmune congenital heart block: complex and unusual situations. Lupus 2016; 25:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eliasson H, Sonesson SE, Sharland G, et al. Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients. Circulation 2011; 124:1919.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Buyon JP, Hiebert R, Copel J, et al. Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry. J Am Coll Cardiol 1998; 31:1658.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson RH, Ho SY. The disposition of the conduction tissues in congenitally malformed hearts with reference to their embryological development. J Perinat Med 1991; 19 Suppl 1:201.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mori AD, Bruneau BG. TBX5 mutations and congenital heart disease: Holt-Oram syndrome revealed. Curr Opin Cardiol 2004; 19:211.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baruteau AE, Fouchard S, Behaghel A, et al. Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study. Eur Heart J 2012; 33:622.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baruteau AE, Behaghel A, Fouchard S, et al. Parental electrocardiographic screening identifies a high degree of inheritance for congenital and childhood nonimmune isolated atrioventricular block. Circulation 2012; 126:1469.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seki A, Ishikawa T, Daumy X, et al. Progressive Atrial Conduction Defects Associated With Bone Malformation Caused by a Connexin-45 Mutation. J Am Coll Cardiol 2017; 70:358.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ho SY, Esscher E, Anderson RH, Michaëlsson M. Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies. Am J Cardiol 1986; 58:291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anderson RH, Wenick AC, Losekoot TG, Becker AE. Congenitally complete heart block. Developmental aspects. Circulation 1977; 56:90.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           NAKAMURA FF, NADAS AS. COMPLETE HEART BLOCK IN INFANTS AND CHILDREN. N Engl J Med 1964; 270:1261.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           ROWE JC, WHITE PD. Complete heart block: a follow-up study. Ann Intern Med 1958; 49:260.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen KM, Mehta A, Rahimtoola SH, Miller RA. Sites of congenital and surgical heart block as defined by His bundle electrocardiography. Circulation 1971; 44:833.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feldt RH, DuShane JW, Titus JL. The atrioventricular conduction system in persistent common atrioventricular canal defect: correlations with electrocardiogram. Circulation 1970; 42:437.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lev M, Silverman J, Fitzmaurice FM, et al. Lack of connection between the atria and the more peripheral conduction system in congenital atrioventricular block. Am J Cardiol 1971; 27:481.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Lev M, Cuadros H, Paul MH. Interruption of the atrioventricular bundle with congenital atrioventricular block. Circulation 1971; 43:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           James TN, Spencer MS, Kloepfer JC. De Subitaneis Mortibus. XXI. Adult onset syncope. with comments on the nature of congenital heart block and the morphogenesis of the human atrioventricular septal junction. Circulation 1976; 54:1001.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reid JM, Coleman EN, Doig W. Complete congenital heart block. Report of 35 cases. Br Heart J 1982; 48:236.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nasrallah AT, Gillette PC, Mullins CE. Congenital and surgical atrioventricular block within the His bundle. Am J Cardiol 1975; 36:914.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sholler GF, Walsh EP. Congenital complete heart block in patients without anatomic cardiac defects. Am Heart J 1989; 118:1193.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Alexander E, Buyon JP, Provost TT, Guarnieri T. Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies. Arthritis Rheum 1992; 35:176.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Miranda-Carús ME, Askanase AD, Clancy RM, et al. Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages. J Immunol 2000; 165:5345.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garcia S, Nascimento JH, Bonfa E, et al. Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts. J Clin Invest 1994; 93:718.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Xiao GQ, Hu K, Boutjdir M. Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block. Circulation 2001; 103:1599.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cruz RB, Viana VS, Nishioka SA, et al. Is isolated congenital heart block associated to neonatal lupus requiring pacemaker a distinct cardiac syndrome? Pacing Clin Electrophysiol 2004; 27:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Askanase AD, Friedman DM, Copel J, et al. Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies. Lupus 2002; 11:145.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nield LE, Silverman ED, Taylor GP, et al. Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis. Circulation 2002; 105:843.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Eliasson H, Sonesson SE, Salomonsson S, et al. Outcome in young patients with isolated complete atrioventricular block and permanent pacemaker treatment: A nationwide study of 127 patients. Heart Rhythm 2015; 12:2278.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Waltuck J, Buyon JP. Autoantibody-associated congenital heart block: outcome in mothers and children. Ann Intern Med 1994; 120:544.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pinsky WW, Gillette PC, Garson A Jr, McNamara DG. Diagnosis, management, and long-term results of patients with congenital complete atrioventricular block. Pediatrics 1982; 69:728.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dewey RC, Capeless MA, Levy AM. Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block. N Engl J Med 1987; 316:835.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Michaëlsson M, Jonzon A, Riesenfeld T. Isolated congenital complete atrioventricular block in adult life. A prospective study. Circulation 1995; 92:442.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Karpawich PP, Gillette PC, Garson A Jr, et al. Congenital complete atrioventricular block: clinical and electrophysiologic predictors of need for pacemaker insertion. Am J Cardiol 1981; 48:1098.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kusumoto FM, Schoenfeld MH, Barrett C, et al. 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2019; 74:e51.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Epstein AE, DiMarco JP, Ellenbogen KA, et al. 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol 2013; 61:e6.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Writing Committee Members, Shah MJ, Silka MJ, et al. 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients. Heart Rhythm 2021; 18:1888.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Baruteau AE, Pass RH, Thambo JB, et al. Congenital and childhood atrioventricular blocks: pathophysiology and contemporary management. Eur J Pediatr 2016; 175:1235.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khairy P, Landzberg MJ, Gatzoulis MA, et al. Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study. Circulation 2006; 113:2391.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chubb H, Mah D, Dubin AM, Moore J. Conduction system pacing in pediatric and congenital heart disease. Front Physiol 2023; 14:1154629.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Izmirly PM, Saxena A, Kim MY, et al. Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus. Circulation 2011; 124:1927.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Levesque K, Morel N, Maltret A, et al. Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome. Autoimmun Rev 2015; 14:1154.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hernstadt H, Regan W, Bhatt H, et al. Cohort study of congenital complete heart block among preterm neonates: a single-center experience over a 15-year period. Eur J Pediatr 2022; 181:1047.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McHenry MM. Factors influencing longevity in adults with congenital complete heart block. Am J Cardiol 1972; 29:416.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Reybrouck T, Vanden Eynde B, Dumoulin M, Van der Hauwaert LG. Cardiorespiratory response to exercise in congenital complete atrioventricular block. Am J Cardiol 1989; 64:896.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Motonaga KS, Punn R, Axelrod DM, et al. Diminished exercise capacity and chronotropic incompetence in pediatric patients with congenital complete heart block and chronic right ventricular pacing. Heart Rhythm 2015; 12:560.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kertesz NJ, Friedman RA, Colan SD, et al. Left ventricular mechanics and geometry in patients with congenital complete atrioventricular block. Circulation 1997; 96:3430.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Moak JP, Barron KS, Hougen TJ, et al. Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela. J Am Coll Cardiol 2001; 37:238.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Udink ten Cate FE, Breur JM, Cohen MI, et al. Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children. J Am Coll Cardiol 2001; 37:1129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pordon CM, Moodie DS. Adults with congenital complete heart block: 25-year follow-up. Cleve Clin J Med 1992; 59:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Groves AM, Allan LD, Rosenthal E. Outcome of isolated congenital complete heart block diagnosed in utero. Heart 1996; 75:190.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Weinreb SJ, Okunowo O, Griffis H, Vetter V. Incidence of morbidity and mortality in a cohort of congenital complete heart block patients followed over 40 years. Heart Rhythm 2022; 19:1149.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thambo JB, Bordachar P, Garrigue S, et al. Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing. Circulation 2004; 110:3766.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chandler SF, Fynn-Thompson F, Mah DY. Role of cardiac pacing in congenital complete heart block. Expert Rev Cardiovasc Ther 2017; 15:853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dandamudi G, Simon J, Cano O, et al. Permanent His Bundle Pacing in Patients With Congenital Complete Heart Block: A Multicenter Experience. JACC Clin Electrophysiol 2021; 7:522.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 912 Version 35.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Sur une maladie infantile et familiale characterisée par des modifications permanentes du pouls, des attaques syncopales et epileptiforme et la mort subite
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Congenital heart block
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/4273004" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Congenital complete heart block: an international study of the natural history.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25800217" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : The clinical spectrum of autoimmune congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9599532" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : [Neonatal lupus syndrome. Association with complete congenital atrioventricular block].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2408004" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Congenital complete atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11755298" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Outcome of children with fetal, neonatal or childhood diagnosis of isolated congenital atrioventricular block. A single institution's experience of 30 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508435" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Risk of congenital complete heart block in newborns of mothers with anti-Ro/SSA antibodies detected by counterimmunoelectrophoresis: a prospective study of 100 women.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11508420" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Anti-Ro/SSA antibodies and congenital heart block: necessary but not sufficient.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26762645" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Autoimmune congenital heart block: complex and unusual situations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21986286" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Isolated atrioventricular block in the fetus: a retrospective, multinational, multicenter study of 175 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9626848" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Autoimmune-associated congenital heart block: demographics, mortality, morbidity and recurrence rates obtained from a national neonatal lupus registry.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1779360" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : The disposition of the conduction tissues in congenitally malformed hearts with reference to their embryological development.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15096952" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : TBX5 mutations and congenital heart disease: Holt-Oram syndrome revealed.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21920962" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Characteristics and long-term outcome of non-immune isolated atrioventricular block diagnosed in utero or early childhood: a multicentre study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22899775" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Parental electrocardiographic screening identifies a high degree of inheritance for congenital and childhood nonimmune isolated atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28705318" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Progressive Atrial Conduction Defects Associated With Bone Malformation Caused by a Connexin-45 Mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3090867" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Anatomy of congenital complete heart block and relation to maternal anti-Ro antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/140774" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Congenitally complete heart block. Developmental aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14133663" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : COMPLETE HEART BLOCK IN INFANTS AND CHILDREN.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13571817" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Complete heart block: a follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5115076" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Sites of congenital and surgical heart block as defined by His bundle electrocardiography.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5451229" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : The atrioventricular conduction system in persistent common atrioventricular canal defect: correlations with electrocardiogram.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5552089" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Lack of connection between the atria and the more peripheral conduction system in congenital atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5578846" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Interruption of the atrioventricular bundle with congenital atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/991400" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : De Subitaneis Mortibus. XXI. Adult onset syncope. with comments on the nature of congenital heart block and the morphogenesis of the human atrioventricular septal junction.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7104115" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Complete congenital heart block. Report of 35 cases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1199947" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Congenital and surgical atrioventricular block within the His bundle.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2480059" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Congenital complete heart block in patients without anatomic cardiac defects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1734907" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Anti-Ro/SS-A antibodies in the pathophysiology of congenital heart block in neonatal lupus syndrome, an experimental model. In vitro electrophysiologic and immunocytochemical studies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11046070" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Anti-SSA/Ro and anti-SSB/La autoantibodies bind the surface of apoptotic fetal cardiocytes and promote secretion of TNF-alpha by macrophages.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8113406" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Cellular mechanism of the conduction abnormalities induced by serum from anti-Ro/SSA-positive patients in rabbit hearts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11257091" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Direct inhibition of expressed cardiac l- and t-type calcium channels by igg from mothers whose children have congenital heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15125717" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Is isolated congenital heart block associated to neonatal lupus requiring pacemaker a distinct cardiac syndrome?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11999879" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Spectrum and progression of conduction abnormalities in infants born to mothers with anti-SSA/Ro-SSB/La antibodies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11854125" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Maternal anti-Ro and anti-La antibody-associated endocardial fibroelastosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26096611" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Outcome in young patients with isolated complete atrioventricular block and permanent pacemaker treatment: A nationwide study of 127 patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8116991" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Autoantibody-associated congenital heart block: outcome in mothers and children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7079038" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Diagnosis, management, and long-term results of patients with congenital complete atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3821827" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Use of ambulatory electrocardiographic monitoring to identify high-risk patients with congenital complete heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7634461" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Isolated congenital complete atrioventricular block in adult life. A prospective study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7304459" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Congenital complete atrioventricular block: clinical and electrophysiologic predictors of need for pacemaker insertion.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30412709" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : 2018 ACC/AHA/HRS Guideline on the Evaluation and Management of Patients With Bradycardia and Cardiac Conduction Delay: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23265327" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : 2012 ACCF/AHA/HRS focused update incorporated into the ACCF/AHA/HRS 2008 guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34363988" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : 2021 PACES Expert Consensus Statement on the Indications and Management of Cardiovascular Implantable Electronic Devices in Pediatric Patients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27351174" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Congenital and childhood atrioventricular blocks: pathophysiology and contemporary management.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16702467" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Transvenous pacing leads and systemic thromboemboli in patients with intracardiac shunts: a multicenter study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/37035676" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Conduction system pacing in pediatric and congenital heart disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21969015" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Maternal and fetal factors associated with mortality and morbidity in a multi-racial/ethnic registry of anti-SSA/Ro-associated cardiac neonatal lupus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26284740" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Description of 214 cases of autoimmune congenital heart block: Results of the French neonatal lupus syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/34704129" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Cohort study of congenital complete heart block among preterm neonates: a single-center experience over a 15-year period.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5060815" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Factors influencing longevity in adults with congenital complete heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2801558" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Cardiorespiratory response to exercise in congenital complete atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/25433143" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : Diminished exercise capacity and chronotropic incompetence in pediatric patients with congenital complete heart block and chronic right ventricular pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9396438" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Left ventricular mechanics and geometry in patients with congenital complete atrioventricular block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11153745" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : Congenital heart block: development of late-onset cardiomyopathy, a previously underappreciated sequela.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11263619" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Dilated cardiomyopathy in isolated congenital complete atrioventricular block: early and long-term risk in children.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1424069" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Adults with congenital complete heart block: 25-year follow-up.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8673760" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : Outcome of isolated congenital complete heart block diagnosed in utero.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/35217197" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Incidence of morbidity and mortality in a cohort of congenital complete heart block patients followed over 40 years.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15583083" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Detrimental ventricular remodeling in patients with congenital complete heart block and chronic right ventricular apical pacing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28875729" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : Role of cardiac pacing in congenital complete heart block.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/33358665" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Permanent His Bundle Pacing in Patients With Congenital Complete Heart Block: A Multicenter Experience.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
